SRPT logo

Sarepta Therapeutics (SRPT) Total Liabilities

Annual Total Liabilities

$2.41 B
-$338.18 M-12.33%

December 31, 2023


Summary


Performance

SRPT Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRPTbalance sheetmetrics:

Quarterly Total Liabilities

$2.38 B
+$31.68 M+1.35%

September 30, 2024


Summary


Performance

SRPT Quarterly Total Liabilities Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSRPTbalance sheetmetrics:

Total Liabilities Formula

Total Liabilities = Current Liabilities + Long-Term Liabilities

SRPT Total Liabilities Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year-12.3%0.0%
3 y3 years+8.2%-12.7%
5 y5 years+294.4%-12.7%

SRPT Total Liabilities Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-year-12.3%+8.3%-13.3%+8.2%
5 y5-year-12.3%+139.4%-13.3%+136.8%
alltimeall time-12.3%>+9999.0%-13.3%>+9999.0%

Sarepta Therapeutics Total Liabilities History

DateAnnualQuarterly
Sep 2024
-
$2.38 B(+1.3%)
Jun 2024
-
$2.35 B(+3.7%)
Mar 2024
-
$2.26 B(-5.9%)
Dec 2023
$2.41 B(-12.3%)
$2.41 B(+2.6%)
Sep 2023
-
$2.35 B(-1.6%)
Jun 2023
-
$2.38 B(+1.6%)
Mar 2023
-
$2.35 B(-14.4%)
Dec 2022
$2.74 B(+23.6%)
$2.74 B(+0.7%)
Sep 2022
-
$2.73 B(+20.0%)
Jun 2022
-
$2.27 B(+3.2%)
Mar 2022
-
$2.20 B(-0.9%)
Dec 2021
$2.22 B(-0.1%)
$2.22 B(+1.2%)
Sep 2021
-
$2.19 B(-3.6%)
Jun 2021
-
$2.27 B(+2.0%)
Mar 2021
-
$2.23 B(+0.3%)
Dec 2020
$2.22 B(+121.3%)
$2.22 B(+17.7%)
Sep 2020
-
$1.89 B(+2.6%)
Jun 2020
-
$1.84 B(+2.1%)
Mar 2020
-
$1.80 B(+79.4%)
Dec 2019
$1.00 B(+64.7%)
$1.00 B(+42.0%)
Sep 2019
-
$707.27 M(+9.0%)
Jun 2019
-
$648.59 M(+5.4%)
Mar 2019
-
$615.33 M(+0.9%)
Dec 2018
$609.80 M(+17.6%)
$609.80 M(+12.3%)
Sep 2018
-
$543.06 M(-0.9%)
Jun 2018
-
$548.11 M(+4.7%)
Mar 2018
-
$523.52 M(+0.9%)
Dec 2017
$518.75 M(+493.4%)
$518.75 M(+403.0%)
Sep 2017
-
$103.13 M(+42.5%)
Jun 2017
-
$72.37 M(-12.2%)
Mar 2017
-
$82.39 M(-5.7%)
Dec 2016
$87.41 M(+4.8%)
$87.41 M(+11.1%)
Sep 2016
-
$78.69 M(-4.7%)
Jun 2016
-
$82.61 M(+11.0%)
Mar 2016
-
$74.40 M(-10.8%)
Dec 2015
$83.44 M(+76.1%)
$83.44 M(+35.6%)
Sep 2015
-
$61.52 M(-7.3%)
Jun 2015
-
$66.33 M(+58.1%)
Mar 2015
-
$41.95 M(-11.5%)
Dec 2014
$47.38 M(+6.8%)
$47.38 M(+44.2%)
Sep 2014
-
$32.85 M(-12.1%)
Jun 2014
-
$37.39 M(-19.5%)
Mar 2014
-
$46.43 M(+4.6%)
Dec 2013
$44.38 M(-45.4%)
$44.38 M(-22.8%)
Sep 2013
-
$57.49 M(-39.4%)
Jun 2013
-
$94.81 M(-10.6%)
Mar 2013
-
$106.06 M(+30.4%)
Dec 2012
$81.31 M(+248.2%)
$81.31 M(+41.1%)
Sep 2012
-
$57.65 M(+194.1%)
Jun 2012
-
$19.60 M(-39.9%)
Mar 2012
-
$32.63 M(+39.7%)
Dec 2011
$23.35 M(-52.1%)
$23.35 M(-20.4%)
Sep 2011
-
$29.33 M(-26.3%)
Jun 2011
-
$39.78 M(-13.7%)
Mar 2011
-
$46.11 M(-5.5%)
Dec 2010
$48.79 M
$48.79 M(+4.5%)
DateAnnualQuarterly
Sep 2010
-
$46.70 M(+16.1%)
Jun 2010
-
$40.23 M(+37.0%)
Mar 2010
-
$29.35 M(-19.4%)
Dec 2009
$36.40 M(+271.2%)
$36.40 M(-20.2%)
Sep 2009
-
$45.62 M(+58.2%)
Jun 2009
-
$28.83 M(+104.1%)
Mar 2009
-
$14.13 M(+44.1%)
Dec 2008
$9.80 M(-20.0%)
$9.80 M(-25.6%)
Sep 2008
-
$13.18 M(+16.2%)
Jun 2008
-
$11.34 M(-22.9%)
Mar 2008
-
$14.69 M(+19.9%)
Dec 2007
$12.26 M(+289.0%)
$12.26 M(+5.3%)
Sep 2007
-
$11.64 M(+66.4%)
Jun 2007
-
$6.99 M(+60.9%)
Mar 2007
-
$4.35 M(+38.0%)
Dec 2006
$3.15 M(+14.7%)
$3.15 M(+44.3%)
Sep 2006
-
$2.18 M(-3.6%)
Jun 2006
-
$2.26 M(+2.5%)
Mar 2006
-
$2.21 M(-19.6%)
Dec 2005
$2.75 M(+22.2%)
$2.75 M(+8.9%)
Sep 2005
-
$2.52 M(+30.9%)
Jun 2005
-
$1.93 M(-15.4%)
Mar 2005
-
$2.28 M(+1.3%)
Dec 2004
$2.25 M(-40.0%)
$2.25 M(+66.7%)
Sep 2004
-
$1.35 M(-37.7%)
Jun 2004
-
$2.17 M(-21.2%)
Mar 2004
-
$2.75 M(-26.7%)
Dec 2003
$3.75 M(-26.8%)
$3.75 M(+62.5%)
Sep 2003
-
$2.31 M(+78.1%)
Jun 2003
-
$1.30 M(-20.0%)
Mar 2003
-
$1.62 M(-68.4%)
Dec 2002
$5.12 M(+56.1%)
$5.12 M(+4.2%)
Sep 2002
-
$4.92 M(+24.3%)
Jun 2002
-
$3.96 M(-16.2%)
Mar 2002
-
$4.72 M(+43.9%)
Dec 2001
$3.28 M(+90.5%)
$3.28 M(+107.5%)
Sep 2001
-
$1.58 M(-2.0%)
Jun 2001
-
$1.61 M(-0.2%)
Mar 2001
-
$1.62 M(-6.1%)
Dec 2000
$1.72 M(+72.3%)
$1.72 M(+30.9%)
Sep 2000
-
$1.32 M(+19.2%)
Jun 2000
-
$1.10 M(+44.0%)
Mar 2000
-
$767.00 K(-23.3%)
Dec 1999
$1.00 M(-16.7%)
$1.00 M(+42.9%)
Sep 1999
-
$700.00 K(+75.0%)
Jun 1999
-
$400.00 K(-42.9%)
Mar 1999
-
$700.00 K(-41.7%)
Dec 1998
$1.20 M(+140.0%)
$1.20 M(0.0%)
Sep 1998
-
$1.20 M(+200.0%)
Jun 1998
-
$400.00 K(-20.0%)
Mar 1998
-
$500.00 K(0.0%)
Dec 1997
$500.00 K(+66.7%)
$500.00 K(-37.5%)
Sep 1997
-
$800.00 K(-11.1%)
Jun 1997
-
$900.00 K(-74.3%)
Mar 1997
-
$3.50 M
Dec 1996
$300.00 K
-

FAQ

  • What is Sarepta Therapeutics annual total liabilities?
  • What is the all time high annual total liabilities for Sarepta Therapeutics?
  • What is Sarepta Therapeutics annual total liabilities year-on-year change?
  • What is Sarepta Therapeutics quarterly total liabilities?
  • What is the all time high quarterly total liabilities for Sarepta Therapeutics?
  • What is Sarepta Therapeutics quarterly total liabilities year-on-year change?

What is Sarepta Therapeutics annual total liabilities?

The current annual total liabilities of SRPT is $2.41 B

What is the all time high annual total liabilities for Sarepta Therapeutics?

Sarepta Therapeutics all-time high annual total liabilities is $2.74 B

What is Sarepta Therapeutics annual total liabilities year-on-year change?

Over the past year, SRPT annual total liabilities has changed by -$338.18 M (-12.33%)

What is Sarepta Therapeutics quarterly total liabilities?

The current quarterly total liabilities of SRPT is $2.38 B

What is the all time high quarterly total liabilities for Sarepta Therapeutics?

Sarepta Therapeutics all-time high quarterly total liabilities is $2.74 B

What is Sarepta Therapeutics quarterly total liabilities year-on-year change?

Over the past year, SRPT quarterly total liabilities has changed by $0.00 (0.00%)